Endocrine

Rates of Digestive Side Effects Linked to Five GLP-1 Diabetes Medicines: A Review and Analysis of Clinical Trials

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated

Full Text

Full text is available at the source.
View Full Text ↗

Funding

Competing interests

Declarations. Conflict of interests: The authors declare no competing interests. Consent to participate: This study did not involve the use of human subjects. Consent to publish: This study did not involve the use of human subjects.
PubMed

Related papers

Jun '25
Digestive Side Effects of Drugs That Activate Glucagon-Like Peptide-1 Receptors: A Comprehensive Review and Analysis
top 1% journal
cited by 30 papers
systematic review
Apr '14
Comparison of Glucagon-like Peptide-1 Drugs and Insulin Glargine for Treating Type 2 Diabetes
top 50% journal
cited by 24 papers
journal article
Jan '21
Comparing SGLT-2 inhibitors and GLP-1 receptor agonists for type 2 diabetes: review and analysis of clinical trials
top 5% journal
cited by 520 papers
systematic review
Jun '21
Possible benefits of diabetes drugs and metformin for polycystic ovary syndrome
top 50% journal
cited by 25 papers
journal article
Apr '23
Benefits and harms of medicines for type 2 diabetes: review and comparison of clinical trials
top 5% journal
cited by 225 papers
systematic review
Sep '24
Comparing seven drugs that target GLP-1 receptors for weight loss in people with obesity or overweight
top 2% journal
cited by 37 papers
systematic review
Jan '18
How well GLP-1 receptor drugs work compared to DPP-4 inhibitors for managing type 2 diabetes: A review of clinical trials
cited by 46 papers
systematic review
Mar '25
Safety and effectiveness of diabetes drugs in people with sleep apnea: a review of clinical trials
top 50% journal
cited by 14 papers
journal article
Feb '25
Safety, effectiveness, and heart benefits of combining SGLT-2 blockers and GLP-1 receptor drugs in people with diabetes
top 20% journal
cited by 28 papers
journal article
Sep '23
Weight loss from GLP-1 receptor drugs in non-diabetic people with overweight or obesity: A combined analysis of clinical trials
cited by 88 papers
systematic review

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #52
GLP-1 drugs linked to lower Parkinson's risk in people with type 2 diabetes
yesterday7 studies
issue #51
Semaglutide linked to nearly double the risk of a rare eye condition in people with diabetes
1 week ago7 studies
issue #50
A once-daily pill beat placebo on weight loss — and it wasn't semaglutide
2 weeks ago7 studies
issue #49
GLP-1 drugs work even without weight loss — and scientists are finally mapping why
3 weeks ago7 studies
issue #48
Stop the drug, regain the weight: pooled data puts the average rebound at 7%
4 weeks ago7 studies
issue #47
The brain region that explains why blocking and activating the same receptor both cause weight loss
5 weeks ago7 studies
issue #46
GLP-1 drugs linked to lower depression and bipolar disorder risk in large genetic study
6 weeks ago7 studies
issue #45
Stopping GLP-1 drugs linked to higher depression and anxiety risk in type 2 diabetes patients
7 weeks ago7 studies
issue #44
Tirzepatide cut all-cause mortality by more than half compared to semaglutide in a 47,000-patient study
8 weeks ago7 studies
issue #43
Semaglutide linked to 21% lower psychiatric hospitalization risk in bipolar disorder patients
9 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief